ArticleNature communications2019
Enantiomeric glycosylated cationic block co-beta-peptides eradicate Staphylococcus aureus biofilms and antibiotic-tolerant persisters.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 137 citations in OpenAlex.
- The rise of ultrashort cationic β-peptides as promising antimicrobial therapeutics.RSC medicinal chemistry · 2025Review
- Inhibitory effects of berberine againstMicrobiology spectrum · 2025Article
- Poly(hexamethylene guanidine): An Effective Compound in Tackling Persistent Bacterial Subpopulations.Microorganisms · 2025Article
- Non-Amphiphilic Antimicrobial Polymers.Angewandte Chemie (International ed. in English) · 2025Article
- Poly-(L-homoarginine) for the non-invasive treatment of endophthalmitis.Materials today. Bio · 2025Article
- Repurposing Etalocib suppresses multidrug-resistant Staphylococcus aureus by disrupting the bacterial membrane.BMC microbiology · 2025Article
- Proteolytic-resistant self-assembling peptide nanofibers combat specific bacterial infections via trap and kill.Science advances · 2025Article
- Carbene formation as a mechanism for efficient intracellular uptake of cationic antimicrobial carbon acid polymers.Nature communications · 2025Article
- Bioinspired Cationic Antimicrobial Polymers.Angewandte Chemie (International ed. in English) · 2025Review
- A biomimetic nano-NET strategy for the treatment of MRSA-related implant-associated infection.RSC advances · 2025Article
- Single-Center Trifunctional Organocatalyst Enables Fast and Controlled Polymerization onACS central science · 2025Article
- Antibacterial and anti-biofilm activities of Derazantinib (ARQ-087) against Staphylococcus aureus.Archives of microbiology · 2025Article
- Open-vessel polymerization of N-carboxyanhydride (NCA) for polypeptide synthesis.Nature protocols · 2025Review
- Recent exploration of γ-AApeptide based antimicrobial peptide mimics as potential therapeutics towards drug-resistant bacteria.Exploration of drug science · 2025Article
- Intrinsic antimicrobial resistance: Molecular biomaterials to combat microbial biofilms and bacterial persisters.Biomaterials · 2024Review
- A Rhein-Based Derivative TargetsAntibiotics (Basel, Switzerland) · 2024Article
- AI-guided few-shot inverse design of HDP-mimicking polymers against drug-resistant bacteria.Nature communications · 2024Article
- Biofilm formation: mechanistic insights and therapeutic targets.Molecular biomedicine · 2023Review
- Unnatural helical peptidic foldamers as protein segment mimics.Chemical Society reviews · 2023Review
- Combating Bacterial Biofilms: Current and Emerging Antibiofilm Strategies for Treating Persistent Infections.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of bacterial infections is hindered by the presence of biofilms and metabolically inactive persisters. Here, we report the synthesis of an enantiomeric block co-beta-peptide, poly(amido-D-glucose)-block-poly(beta-L-lysine), with high yield and purity by one-shot one-pot anionic-ring opening (co)polymerization. The co-beta-peptide is bactericidal against methicillin-resistant Staphylococcus aureus (MRSA), including replicating, biofilm and persister bacterial cells, and also disperses biofilm biomass. It is active towards community-acquired and hospital-associated MRSA strains which are resistant to multiple drugs including vancomycin and daptomycin. Its antibacterial activity is superior to that of vancomycin in MRSA mouse and human ex vivo skin infection models, with no acute in vivo toxicity in repeated dosing in mice at above therapeutic levels. The copolymer displays bacteria-activated surfactant-like properties, resulting from contact with the bacterial envelope. Our results indicate that this class of non-toxic molecule, effective against different bacterial sub-populations, has promising potential for the treatment of S. aureus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.